Strides Arcolab has received US FDA approval for Clindamycin Injection, USP, an antibiotic used to treat bacterial infections. Clindamycin Injection will be available in three single dose vial sizes and in pharmacy bulk packaging. As with all products in Strides- Sagent JV, Clindamycin features the prevent IV measures packaging and labeling designed to aid in reduction of the medication errors.
According to the IMS, the 2011 US market for injectable Clindamycin approximates to $65 million. The product is expected to be launched in early 2012. Clindamycin is the twelfth product approved under the Sagent-Strides partnership. The company is developing and supplying more than 25 injectables products for the USA market which will be marketed by Sagent.
